Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CYR61 (cysteine-rich, angiogenic inducer, 61)

Written2013-01Chih-Chiun Chen, Lester F Lau
Department of Biochemistry, Molecular Genetics, University of Illinois at Chicago, 900 South Ashland Avenue, Chicago, IL 60607, USA

(Note : for Links provided by Atlas : click)

Identity

Alias_namesIGFBP10
cysteine-rich
Alias_symbol (synonym)GIG1
CCN1
Other alias
HGNC (Hugo) CYR61
LocusID (NCBI) 3491
Atlas_Id 40256
Location 1p22.3  [Link to chromosome band 1p22]
Location_base_pair Starts at 86046444 and ends at 86049648 bp from pter ( according to hg19-Feb_2009)  [Mapping CYR61.png]
Fusion genes
(updated 2016)
CYR61 (1p22.3) / COL6A1 (21q22.3)CYR61 (1p22.3) / EPAS1 (2p21)CYR61 (1p22.3) / KCTD15 (19q13.11)
OAS1 (12q24.13) / CYR61 (1p22.3)
Note CYR61 (cysteine-rich angiogenic inducer 61; also named CCN1), first identified as a serum-inducible immediate-early gene, encodes a secreted, extracellular matrix-associated protein that regulates diverse cellular functions (Lau, 2011). CYR61 and five later identified homologs comprise the six-member CCN family, named after the first three members described: CYR61, CTGF (connective tissue growth factor; CCN2), and NOV (nephroblastoma overexpressed; CCN3) (Jun and Lau, 2011). By international consensus, these genes have now been renamed CCN1-6 (Brigstock et al., 2003).

DNA/RNA

 
  CYR61 is located on chromosome 1, 86046 kbp ~ 86049 kbp from the p-arm telomere (pter). Each exon is depicted as a box with a unique color, with the numbers of exons shown above. Mature mRNA is ~2,3 kbp in length plus a poly-A tail.
Description Gene structure
The transcribed region of the CYR61 genomic locus spans ~3,2 kb, with 5 exons interspaced by 4 introns. The first exon encodes the 5' untranslated region of the mRNA and followed by sequences encoding the protein secretory signal peptide. The remaining 4 exons each encode a discrete CYR61 domain, and the last exon also contains the mRNA 3' untranslated sequence (O'Brien et al., 1990). The 2 kb DNA upstream of the transcription start site contains sufficient information as the Cyr61 promoter to drive accurate expression in transgenic mice both during embryonic development and in adult wound healing (Latinkic et al., 2001). Since each CYR61 domain is encoded by a discrete exon, it was hypothesized that CYR61 arose through an exon-shuffling mechanism (Brigstock, 1999; Lau and Lam, 1999).

SNP
rs3753794 and rs3753793 (r2= 0.77) were associated plasma HDL-cholesterol levels (p= 0.016 and p= 0.008) (Bouchard et al., 2007).
rs954353, located 1,8 kb upstream of CYR61, is linked to susceptibility to colorectal cancer (Fernández-Rozadilla et al., 2010).

Transcription The CYR61 promoter is a TATA-box promoter containing binding sites for many transcription factors including AP1, ATF, E2F, HNF3b, NF1, NFkB, SP1, and SRF, and 2 poly(CA) stretches that may form Z-DNA structure. CYR61 transcription is highly responsive to induction by serum growth factors, cytokines, hormones (angiotensin II, estrogen, vitamin D3), and environmental perturbations including UV irradiation, hypoxia, and mechanical stress. During mouse embryo development Cyr61 is highly expressed in cardiovascular, neuronal, and skeletal systems. In adulthood CYR61 is induced at sites of inflammation and wound repair, and de-regulated in many forms of cancer.
Internal ribosome entry site: CYR61 mRNA contains a highly conserved, guanine-cytosine (GC)-rich region of approximately 200 bp near the 5'-end of the open reading frame which serves as an internal ribosome entry site (Mukudai et al., 2010). It may facilitate CYR61 production in stressful conditions such as during viral infection (Johannes et al., 1999).
Alternative splicing: hypoxia during breast carcinogenesis may promote a shift of CYR61 alternative splicing to promote CYR61 production. In normal breast tissue most CYR61 RNA transcript contains intron-3, which does not produce CYR61 protein. In cancerous tissues that often suffer hypoxia, intron-3 is spliced out, resulting in mature CYR61 mRNA and a higher level of CYR61 production (Hirschfeld et al., 2009; Hirschfeld et al., 2011).
3'-UTR: CYR61 3'UTR contains 5 copies of AU-rich element (ARE) in the 3'-UTR, which causes RNA instability (Leng et al., 2002). In addition, CYR61 mRNA 3'-UTR contains a microRNA-155 target site. In preeclampsia where placental miR-155 level is high, CYR61 mRNA is reduced due to targeted degradation by miR-155 (Zhang et al., 2010).
Pseudogene None identified yet.

Protein

Note CYR61 is a secreted protein located in the extracellular matrix and on cell surface (Yang and Lau, 1991), and regulates diverse cellular activity including cell adhesion, migration, proliferation, apoptosis, senescence, and differentiation (Lau, 2011). It binds to and acts through cell surface integrin receptors, with heparan sulfate proteoglycans (HSPGs) as coreceptors in some contexts (Chen and Lau, 2009; Lau, 2011). Cell adhesion to CYR61 as a substrate induces activation of various signaling molecules including Rac1, FAK, the MAP kinases ERK1/ERK2, and transcription factors such as NFκB (Chen et al., 2001a; Bai et al., 2010). CYR61 is a strong inducer of intracellular reactive oxygen species (ROS) through multiple cellular sources including NADPH Oxidase, 5-lipoxygenase, sphingomyelinase, and the mitochondria; accumulation of ROS mediates Cyr61-promoted apoptosis and cellular senescence (Chen CC et al., 2007; Jun and Lau, 2010b; Juric et al., 2012).
Targeted Cyr61 deletion in mice is embryonic lethal due to cardiac atrioventricular septal defects, impaired placentation, and compromised blood vessel integrity (Mo et al., 2002; Mo and Lau, 2006). Consistently, CYR61 induces pro-angiogenic activity in endothelial cells in culture and neovascularization in vivo (Babic et al., 1998; Fataccioli et al., 2002; Leu et al., 2002).
In adulthood Cyr61 expression is strongly associated with inflammation and wound repair (Lau, 2011). In particular, Cyr61 plays a critical role in the resolution of fibrosis during wound healing by inducing cellular senescence in myofibroblasts (Jun and Lau, 2010b). In inflammation, CYR61 is critical for TNFα-mediated apoptosis in vivo, and can enhance the cytotoxicity of other TNF family cytokines including LTα, FasL, and TRAIL (Chen CC et al., 2007; Franzen et al., 2009; Juric et al., 2009). Finally, CYR61 expression is de-regulated in most human chronic inflammatory diseases including rheumatoid arthritis, diabetic retinopathy and nephropathy, atherosclerosis, and many cancers (Lau, 2011).
 
  Each domain is depicted as a box with a unique color, with the domain name shown in the box. The grey box represents the secretory signal peptide. Integrin/HSPGs binding sites are marked as stripes.
Description Domain structure, receptor binding sites, and interacting proteins
Full-length CYR61 precursor is 381 amino acids in length, with aa 1-24 being the secretory signal peptide. The calculated molecular size for mature CYR61 is 39,4 kDa, and on SDS-PAGE it migrates as a ~40 kDa protein band. CYR61 contains unusually high cysteine content (37 cysteines in the processed protein), in addition, all cysteines are completely conserved among CCN1, CCN2, CCN3, and CCN4.
CYR61 is a direct ligand of several integrin receptors, including αvβ3, αvβ5, αIIbβ3, αMβ2, and α6β1, and has strong binding for cell surface HSPGs (Kireeva et al., 1998; Jedsadayanmata et al., 1999; Chen et al., 2000; Grzeszkiewicz et al., 2002; Schober et al., 2002). Cyr61 binds preferentially to particular integrins in a cell-type specific manner, and this interaction mediates many activities of CYR61.
Proteins of the CCN protein family consists of four structural domains (Holbourn et al., 2008). The first CYR61 domain has sequence homologies to insulin-like growth factor binding protein (IGFBP), although CYR61 does not bind IGFs. The second domain is homologous to the von Willebrand Factor type C repeat (vWC). It has a functional integrin αvβ3 binding site with the sequence NCKHQCTCIDGAVGCIPLCP from aa 116 to 135 (Chen et al., 2004). A point mutation substituting the center aspartic acid residue to alanine (D125A mutation) eliminates the binding activity. Consistent with the notion that CYR61 induces angiogenesis through direct binding to integrin αvβ3, the D125A mutation in Cyr61 effectively abrogates its angiogenic activity (Chen et al., 2004).
Following the vWC-domain is a hinge-region that does not seem to have a particular 3d structure, and its aa sequence is not conserved among the CCN-family members.
The third domain has homology to thrombospondin type 1 repeat (TSR). It contains an integrin α6β1 binding site called T1 with the sequence TTSWSQCSKS from aa 231-240 (Leu et al., 2003).
The fourth domain (CT) has homology to the cysteine-knot motif, and has two binding sites to integrin α6β1 and HSPGs called H1 (aa 278-295, YSSLKKGKKCSKTKKSPE) and H2 (aa 302-314, SSVKKYRPKYCGS), each contributes to heparin binding and integrin α6β1/HSPGs-mediated fibroblast cell adhesion (Chen et al., 2000). The H2 site also overlaps a binding site for integrin αMβ2 and can mediate monocyte cell adhesion (Schober et al., 2002).
The domains of CYR61 may function independently. A mutant CYR61 protein with the CT-domain deleted is unable to induce fibroblast cell adhesion, but still able to activate αv integrin-mediated activities, including cell migration, and potentiate bFGF-induced cell proliferation (Grzeszkiewicz et al., 2001). Similarly, a CYR61 mutant protein (DM) with disrupted integrin α6β1/HSPGs-binding sites is defective for CYR61 supported fibroblast functions, but can still promoting αv integrin-mediated angiogenic activities (Chen et al., 2004). The N-terminal half of CYR61 alone, which contains domains 1 and 2, can bind purified integrin αvβ3 and mediate endothelial cell adhesion (Chen et al., 2004). Mixing CYR61-D125A (mutated in the αv integrin binding site), with CYR61-DM (mutated in the α6β1/HSPG binding sites) can reconstitute wild-type CYR61 function to synergize with TNFα and induce fibroblast apoptosis (Chen CC et al., 2007).

Mutations

Germinal The CYR61 gene is located in human chromosome 1p22.3, within the region of a susceptibility gene locus for atrioventricular septal defects (AVSD; 1p21-1p31) (Sheffield et al., 1997). Targeted disruption of Cyr61 in mice results in severe atrioventricular septal defects (AVSD). Furthermore, Cyr61 haploinsufficiency results in delayed formation of the ventricular septa in embryos and persistent ostium primum atrial septal defects (ASD) in ≈20% of adults (Mo and Lau, 2006).

Implicated in

Note
  
Entity Cancer
Note CYR61 expression is regulated by a wide array of growth factors, inflammatory cytokines, and hormones, which are often de-regulated in cancerous tissues. CYR61 protein is a potent context-dependent regulator of many cellular functions important in tumorigenesis, including cell proliferation, survival/apoptosis, senescence, motility/chemotaxis, invasion in extracellular matrix, gene expression, differentiation, and angiogenesis. Perhaps as a consequence CYR61 is aberrantly expressed in most forms of solid tumors where, depending on cancer types, it may have either promoting or suppressing roles. Many research works are ongoing to understand CYR61 function in the context of each specific type of cancer, which may in the future lead to better prognostic tools and cancer treatment.
  
  
Entity Breast cancer
Note CYR61 may have a role in breast cancer progression and the development of resistance to anti-cancer drugs. CYR61 expression is associated with more advanced cancer features, including tumor stage, size, lymph node infiltration, age, and estrogen receptor expression (Xie et al., 2001). Over-expressing CYR61 in the breast cancer cell line MCF-7 can induce estrogen-independent cell growth, and promote tumorigenesity in nude mice (Tsai et al., 2002). CYR61 over-expression confers cellular resistance to apoptosis induction by anti-cancer drugs including Taxol, Adriamycin, and β-lapachone (Lin et al., 2004; Menendez et al., 2005). In addition, CYR61 induction by the Hippo-LATS signaling pathway enables Taxol resistance in breast cancer cells (Lai et al., 2011). These results suggest CYR61 may be a novel therapeutic target in treating drug-resistant breast cancers.
  
  
Entity Endometrial cancer
Note CYR61 expression in endometrial cancers is down-regulated when compared to matched normal endometrial tissue, suggesting it may have a tumor-suppressing role (Chien et al., 2004). Consistent with the idea, over-expressing CYR61 in the endometrial cancer cell line AN3CA decreased cell growth in vitro, and abrogated tumorigenicity in nude mice (Chien et al., 2004). Moderate to high CYR61 levels are detectable by immunohistochemical analysis in ~50% of endometrioid adenocarcinoma, the most common form of endometrial cancer. However its expression is not associated with pathological features including age, cancer stage, invasion to surrounding tissues, or lymph node metastasis (Watari et al., 2009).
  
  
Entity Ovarian cancer
Note CYR61 mRNA in ovarian cancer tissues is up-regulated in ~60% patients with a range from 2 to 10 fold higher than that found in normal ovary samples. Its over-expression is also associated with higher disease stages (Gery et al., 2005). In ovarian cancer cell lines, CYR61 promotes cell proliferation, enhances tumor growth in nude mice, and confers resistance to cytotoxicity by the anti-cancer drug carboplatin (Gery et al., 2005). These results suggest that CYR61 may have a promoting role in ovarian cancer.
  
  
Entity Prostate cancer
Note CYR61 may promote primary prostate cancer in situ but repress the spreading of prostate cancer cells after surgical removal of the primary tumor. Its expression is up-regulated in benign prostate hyperplasia compared to normal prostate tissues (Sakamoto et al., 2004), and higher in prostate cancer than in normal (D'Antonio et al., 2010b) and benign hyperplasia tissues (Lv et al., 2009). In addition, CYR61 supports cell adhesion and proliferation in prostate epithelial and cancer cells (Franzen et al., 2009; Sakamoto et al., 2004). Together these results show CYR61 may have a promoting role in prostate cancer. However, higher CYR61 expression is associated with >50% reduced cancer recurrence rates in patients after radical prostatectomy for clinically localized prostate cancer (D'Antonio et al., 2010a). In addition CYR61 can cooperate with TRAIL to induce prostate cancer cell apoptosis (Franzen et al., 2009). It is hypothesized that CYR61 may function in a TRAIL-dependent immune surveillance mechanism to repress potential prostate cancer cell spreading in the hosts leading to reduced cancer recurrence.
  
  
Entity Lung cancer
Note CYR61 acts as a tumor-suppressor in lung cancers. Its mRNA level in lung tumor is decreased compared to adjacent non-cancerous tissues, and more reduced expression is associated with more advanced disease and poorer patient survival rates (Chen PP et al., 2007; Mori et al., 2007). Stable ectopic expression of CYR61 in non-small cell lung carcinoma cell lines caused cell cycle arrests in G1, elevated p53 and p21 expression, and reduced tumorigenecity in nude mice (Tong et al., 2001).
  
  
Entity Osteosarcoma
Note Immunohistochemical analysis of osteosarcoma tissue microarrays using anti-CYR61 antibodies shows that higher CYR61 levels are associated with higher tumor grades and shorter patient survival (Sabile et al., 2012; Fromigue et al., 2011). Over-expressing CYR61 in osteosarcoma cell lines enhanced tumorigenecity and lung metastasis in nude mice (Sabile et al., 2012), while silencing CYR61 abrogated cell Matrigel invasion in vitro, and lung metastasis in vivo (Fromigue et al., 2011). These results suggest that CYR61 may promote osteosarcoma tumorigenesis and metastasis.
  
  
Entity Pancreatic cancer
Note Elevated CYR61 in pancreatic ductal adenocarcinoma compared to adjacent normal tissue was detected in patient tissue samples by in situ hybridization and immunihistochemical analysis (Haque et al., 2012; Haque et al., 2011). In a human pancreatic cancer cell line Panc-1, CYR61 expression is necessary for cellular expression of stem cell-like phenotype and cell migration, and tumorigenesis in nude mice (Haque et al., 2011). CYR61 may act by binding integrin alphavbeta3 to suppress cellular Notch-1 proteosome degradation, leading to the activation of Sonic Hedgehog signaling and cell migration (Haque et al., 2012).
  
  
Entity Glioma
Note CYR61 has promoting roles in glioma tumorigenesis. Its mRNA and protein levels are elevated compared to normal brain tissues, and in addition, its aberrant expression is associated with higher cancer grades and poor prognosis (Xie et al., 2004a; Goodwin et al., 2010). Over-expressing CYR61 in glioma cells in vitro activates ILK, Akt, and GSK3/b-catenin signaling, and promotes pro-tumorigenic cellular activities including proliferation, colony-formation in soft agar, and cell migration. Forced CYR61 expression in glioma cells enhanced tumorigenicity when xenografted in nude mice (Xie et al., 2004a), while injecting CYR61 siRNA in pre-established tumor xenografts reduced cell proliferation and tumor growth (Goodwin et al., 2010).
  
  
Entity Colorectal cancer
Note CYR61 mRNA levels are ~10-fold higher in colorectal cancers compared to that in normal colon tissues. However expression is reduced in more advanced cancers and there is no statistically significant association between CYR61 and pathological parameters (Ladwa et al., 2011).
  
  
Entity Wound healing and fibrogenesis
Note CYR61 expression is highly induced during injury/repair of many tissue and organs, including in the granulation tissue of skin wounds (Chen et al., 2001b; Rittié et al., 2011), liver after partial hepatectomy (Su et al., 2002), the callus in the healing bone (Hadjiargyrou et al., 2000; Lienau et al., 2006), and the heart after myocardial infarction (Hilfiker-Kleiner et al., 2004).
Tissue wound repair in mammals occurs in three distinct but overlapping phases: inflammation, followed by formation of granulation tissues (fibroblasts activation, proliferation, fibrogenesis, and angiogenesis), and finally remodeling and resolution of the granulation tissue to form the mature tissue (Gurtner et al., 2008). Resident fibroblasts and recruited fibrocytes are activated in wounds to proliferate and become myofibroblasts, which rapidly synthesize extracellular matrix. The matrix is important for maintaining tissue integrity and may help parenchymal cell regeneration. CYR61 is highly expressed in the granulation tissue during the resolution phase in skin wounds, where CYR61 drives fibrogenic myofibroblasts to become senescent cells. Senescent myofibroblasts cease to proliferate and express an anti-fibrotic phenotype, including the enhanced expression of matrix degradation enzymes to help resolution of fibrosis (Rodier and Campisi, 2011; Jun and Lau, 2010b; Jun and Lau, 2010a).
  
  
Entity Diabetic retinopathy and nephropathy
Note Cyr61 may contribute to diabetic retinopathy. Its expression is induced by advanced glycation end products (Hughes et al., 2007). In proliferative diabetic retinal membrane CYR61 is induced in ganglion cells, endothelial cells, and smooth muscle cells, where it may contribute to the loss of normal capillary pericytes by apoptosis (Liu et al., 2008) and enhancement of aberrant neovascularization (Zhang et al., 2012). Elevated CYR61 in vitreous is detected in patients with proliferative diabetic retinopathy (You et al., 2012). In the normal adult kidney CYR61 is expressed by podocytes and tubular epithelial cells, where CYR61 may function to maintain normal podocyte differentiation, but suppress mesangial cell adhesion and migration (Sawai et al., 2007). Podocyte expression of Cyr61 is diminished in patients with diabetic nephropathy, and this may be associated with mesangial expansion in glomerulopathies (Sawai et al., 2007).
  
  
Entity Vascular disease
Note CYR61 is induced in human arteriosclerotic lesions (Hilfiker et al., 2002) and inflammatory cardiomyopathy (Rother et al., 2010).
  
  
Entity Inflammatory diseases
Note CYR61 is highly expressed in rheumatoid arthritis (Zhang et al., 2009) as well as in patients with Crohn's disease or ulcerative colitis (Koon et al., 2008).
  

Bibliography

CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.
Babic AM, Kireeva ML, Kolesnikova TV, Lau LF.
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6355-60.
PMID 9600969
 
Matricellular protein CCN1 activates a proinflammatory genetic program in murine macrophages.
Bai T, Chen CC, Lau LF.
J Immunol. 2010 Mar 15;184(6):3223-32. doi: 10.4049/jimmunol.0902792. Epub 2010 Feb 17.
PMID 20164416
 
CYR61 polymorphisms are associated with plasma HDL-cholesterol levels in obese individuals.
Bouchard L, Tchernof A, Deshaies Y, Lebel S, Hould FS, Marceau P, Vohl MC.
Clin Genet. 2007 Sep;72(3):224-9.
PMID 17718860
 
Proposal for a unified CCN nomenclature.
Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, Lyons K, Naus C, Perbal B, Riser B, Takigawa M, Yeger H.
Mol Pathol. 2003 Apr;56(2):127-8.
PMID 12665631
 
The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts.
Chen CC, Chen N, Lau LF.
J Biol Chem. 2001a Mar 30;276(13):10443-52. Epub 2000 Dec 18.
PMID 11120741
 
Functions and mechanisms of action of CCN matricellular proteins.
Chen CC, Lau LF.
Int J Biochem Cell Biol. 2009 Apr;41(4):771-83. doi: 10.1016/j.biocel.2008.07.025. Epub 2008 Aug 15.
PMID 18775791
 
The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts.
Chen CC, Mo FE, Lau LF.
J Biol Chem. 2001b Dec 14;276(50):47329-37. Epub 2001 Oct 2.
PMID 11584015
 
Cytotoxicity of TNFalpha is regulated by integrin-mediated matrix signaling.
Chen CC, Young JL, Monzon RI, Chen N, Todorovic' V, Lau LF.
EMBO J. 2007 Mar 7;26(5):1257-67. Epub 2007 Feb 22.
PMID 17318182
 
Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteoglycans.
Chen N, Chen CC, Lau LF.
J Biol Chem. 2000 Aug 11;275(32):24953-61.
PMID 10821835
 
Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
Chen N, Leu SJ, Todorovic V, Lam SC, Lau LF.
J Biol Chem. 2004 Oct 15;279(42):44166-76. Epub 2004 Aug 10.
PMID 15308622
 
Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer.
Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D.
PLoS One. 2007 Jun 20;2(6):e534.
PMID 17579708
 
Cyr61 suppresses growth of human endometrial cancer cells.
Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, Koeffler HP.
J Biol Chem. 2004 Dec 17;279(51):53087-96. Epub 2004 Oct 7.
PMID 15471875
 
Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.
J Urol. 2010b Apr;183(4):1604-10. doi: 10.1016/j.juro.2009.12.006. Epub 2010 Feb 20.
PMID 20172544
 
Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate.
Fataccioli V, Abergel V, Wingertsmann L, Neuville P, Spitz E, Adnot S, Calenda V, Teiger E.
Hum Gene Ther. 2002 Aug 10;13(12):1461-70.
PMID 12215267
 
Colorectal cancer susceptibility quantitative trait loci in mice as a novel approach to detect low-penetrance variants in humans: a two-stage case-control study.
Fernandez-Rozadilla C, Tarrio R, Clofent J, de Castro L, Brea-Fernandez A, Bessa X, Abuli A, Andreu M, Jover R, Xicola R, Llor X, Castells A, Castellvi-Bel S, Carracedo A, Ruiz-Ponte C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):619-23. doi: 10.1158/1055-9965.EPI-09-1175.
PMID 20142256
 
Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis.
Franzen CA, Chen CC, Todorovic' V, Juric V, Monzon RI, Lau LF.
Mol Cancer Res. 2009 Jul;7(7):1045-55. doi: 10.1158/1541-7786.MCR-09-0017. Epub 2009 Jul 7.
PMID 19584265
 
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B, Marie PJ.
J Bone Miner Res. 2011 Jul;26(7):1533-42. doi: 10.1002/jbmr.343.
PMID 21312266
 
Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.
Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP.
Clin Cancer Res. 2005 Oct 15;11(20):7243-54.
PMID 16243794
 
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR, Lal B, Zhou X, Ho S, Xia S, Taeger A, Murray J, Laterra J.
Cancer Res. 2010 Apr 1;70(7):2932-41. doi: 10.1158/0008-5472.CAN-09-3570. Epub 2010 Mar 16.
PMID 20233866
 
The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans.
Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF.
Endocrinology. 2002 Apr;143(4):1441-50.
PMID 11897702
 
Wound repair and regeneration.
Gurtner GC, Werner S, Barrandon Y, Longaker MT.
Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039.
PMID 18480812
 
Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair.
Hadjiargyrou M, Ahrens W, Rubin CT.
J Bone Miner Res. 2000 Jun;15(6):1014-23.
PMID 10841170
 
The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis.
Haque I, De A, Majumder M, Mehta S, McGregor D, Banerjee SK, Van Veldhuizen P, Banerjee S.
J Biol Chem. 2012 Nov 9;287(46):38569-79. doi: 10.1074/jbc.M112.389064. Epub 2012 Oct 1.
PMID 23027863
 
Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.
Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, Van Veldhuizen PJ, Banerjee SK, Banerjee S.
Mol Cancer. 2011 Jan 13;10:8. doi: 10.1186/1476-4598-10-8.
PMID 21232118
 
Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II.
Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ, Schieffer B, Drexler H.
Circulation. 2002 Jul 9;106(2):254-60.
PMID 12105167
 
Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation.
Hilfiker-Kleiner D, Kaminski K, Kaminska A, Fuchs M, Klein G, Podewski E, Grote K, Kiian I, Wollert KC, Hilfiker A, Drexler H.
Circulation. 2004 May 11;109(18):2227-33. Epub 2004 Apr 26.
PMID 15117851
 
Expression of tumor-promoting Cyr61 is regulated by hTRA2-?1 and acidosis.
Hirschfeld M, Jaeger M, Buratti E, Stuani C, Grueneisen J, Gitsch G, Stickeler E.
Hum Mol Genet. 2011 Jun 15;20(12):2356-65. doi: 10.1093/hmg/ddr128. Epub 2011 Mar 29.
PMID 21447598
 
The CCN family of proteins: structure-function relationships.
Holbourn KP, Acharya KR, Perbal B.
Trends Biochem Sci. 2008 Oct;33(10):461-73. doi: 10.1016/j.tibs.2008.07.006. Epub 2008 Sep 11.
PMID 18789696
 
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina.
Hughes JM, Kuiper EJ, Klaassen I, Canning P, Stitt AW, Van Bezu J, Schalkwijk CG, Van Noorden CJ, Schlingemann RO.
Diabetologia. 2007 May;50(5):1089-98. Epub 2007 Feb 28.
PMID 17333105
 
Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3).
Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC.
J Biol Chem. 1999 Aug 20;274(34):24321-7.
PMID 10446209
 
Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray.
Johannes G, Carter MS, Eisen MB, Brown PO, Sarnow P.
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13118-23.
PMID 10557283
 
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.
Jun JI, Lau LF.
Nat Rev Drug Discov. 2011 Dec 1;10(12):945-63. doi: 10.1038/nrd3599.
PMID 22129992
 
TNFa-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release.
Juric V, Chen CC, Lau LF.
PLoS One. 2012;7(2):e31303. doi: 10.1371/journal.pone.0031303. Epub 2012 Feb 17.
PMID 22363611
 
Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3.
Kireeva ML, Lam SC, Lau LF.
J Biol Chem. 1998 Jan 30;273(5):3090-6.
PMID 9446626
 
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis.
Koon HW, Zhao D, Xu H, Bowe C, Moss A, Moyer MP, Pothoulakis C.
Am J Pathol. 2008 Aug;173(2):400-10. doi: 10.2353/ajpath.2008.080222. Epub 2008 Jul 3.
PMID 18599605
 
Expression of CTGF and Cyr61 in colorectal cancer.
Ladwa R, Pringle H, Kumar R, West K.
J Clin Pathol. 2011 Jan;64(1):58-64. doi: 10.1136/jcp.2010.082768. Epub 2010 Nov 15.
PMID 21081514
 
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.
Lai D, Ho KC, Hao Y, Yang X.
Cancer Res. 2011 Apr 1;71(7):2728-38. doi: 10.1158/0008-5472.CAN-10-2711. Epub 2011 Feb 24.
PMID 21349946
 
Promoter function of the angiogenic inducer Cyr61gene in transgenic mice: tissue specificity, inducibility during wound healing, and role of the serum response element.
Latinkic BV, Mo FE, Greenspan JA, Copeland NG, Gilbert DJ, Jenkins NA, Ross SR, Lau LF.
Endocrinology. 2001 Jun;142(6):2549-57.
PMID 11356704
 
The CCN family of angiogenic regulators: the integrin connection.
Lau LF, Lam SC.
Exp Cell Res. 1999 Apr 10;248(1):44-57.
PMID 10094812
 
CCN1/CYR61: the very model of a modern matricellular protein.
Lau LF.
Cell Mol Life Sci. 2011 Oct;68(19):3149-63. doi: 10.1007/s00018-011-0778-3. Epub 2011 Jul 31.
PMID 21805345
 
Organization and expression of the Cyr61 gene in normal human fibroblasts.
Leng E, Malcolm T, Tai G, Estable M, Sadowski I.
J Biomed Sci. 2002 Jan-Feb;9(1):59-67.
PMID 11810026
 
Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells.
Leu SJ, Lam SC, Lau LF.
J Biol Chem. 2002 Nov 29;277(48):46248-55. Epub 2002 Oct 2.
PMID 12364323
 
Identification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61).
Leu SJ, Liu Y, Chen N, Chen CC, Lam SC, Lau LF.
J Biol Chem. 2003 Sep 5;278(36):33801-8. Epub 2003 Jun 24.
PMID 12826661
 
CYR61 (CCN1) protein expression during fracture healing in an ovine tibial model and its relation to the mechanical fixation stability.
Lienau J, Schell H, Epari DR, Schutze N, Jakob F, Duda GN, Bail HJ.
J Orthop Res. 2006 Feb;24(2):254-62.
PMID 16435358
 
Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.
Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML.
J Biol Chem. 2004 Jun 4;279(23):24015-23. Epub 2004 Mar 24.
PMID 15044484
 
Cysteine-rich protein 61 and connective tissue growth factor induce deadhesion and anoikis of retinal pericytes.
Liu H, Yang R, Tinner B, Choudhry A, Schutze N, Chaqour B.
Endocrinology. 2008 Apr;149(4):1666-77. doi: 10.1210/en.2007-1415. Epub 2008 Jan 10.
PMID 18187544
 
Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status.
Lv H, Fan E, Sun S, Ma X, Zhang X, Han DM, Cong YS.
J Cell Biochem. 2009 Mar 1;106(4):738-44. doi: 10.1002/jcb.22075.
PMID 19180570
 
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R.
Oncogene. 2005 Jan 27;24(5):761-79.
PMID 15592521
 
The matricellular protein CCN1 is essential for cardiac development.
Mo FE, Lau LF.
Circ Res. 2006 Oct 27;99(9):961-9. Epub 2006 Oct 5.
PMID 17023674
 
CYR61 (CCN1) is essential for placental development and vascular integrity.
Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF.
Mol Cell Biol. 2002 Dec;22(24):8709-20.
PMID 12446788
 
CYR61: a new measure of lung cancer outcome.
Mori A, Desmond JC, Komatsu N, O'Kelly J, Miller CW, Legaspi R, Marchevsky AM, McKenna RJ Jr, Koeffler HP.
Cancer Invest. 2007 Dec;25(8):738-41.
PMID 18058471
 
A coding RNA segment that enhances the ribosomal recruitment of chicken ccn1 mRNA.
Mukudai Y, Kubota S, Eguchi T, Sumiyoshi K, Janune D, Kondo S, Shintani S, Takigawa M.
J Cell Biochem. 2010 Dec 15;111(6):1607-18. doi: 10.1002/jcb.22894.
PMID 21053272
 
Expression of cyr61, a growth factor-inducible immediate-early gene.
O'Brien TP, Yang GP, Sanders L, Lau LF.
Mol Cell Biol. 1990 Jul;10(7):3569-77.
PMID 2355916
 
Spatial-temporal modulation of CCN proteins during wound healing in human skin in vivo.
Rittie L, Perbal B, Castellot JJ Jr, Orringer JS, Voorhees JJ, Fisher GJ.
J Cell Commun Signal. 2011 Mar;5(1):69-80. doi: 10.1007/s12079-010-0114-y. Epub 2011 Jan 11.
PMID 21484592
 
Four faces of cellular senescence.
Rodier F, Campisi J.
J Cell Biol. 2011 Feb 21;192(4):547-56. doi: 10.1083/jcb.201009094. Epub 2011 Feb 14.
PMID 21321098
 
Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator.
Rother M, Krohn S, Kania G, Vanhoutte D, Eisenreich A, Wang X, Westermann D, Savvatis K, Dannemann N, Skurk C, Hilfiker-Kleiner D, Cathomen T, Fechner H, Rauch U, Schultheiss HP, Heymans S, Eriksson U, Scheibenbogen C, Poller W.
Circulation. 2010 Dec 21;122(25):2688-98. doi: 10.1161/CIRCULATIONAHA.110.945261. Epub 2010 Dec 6.
PMID 21135363
 
Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice.
Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W, Fuchs B.
J Bone Miner Res. 2012 Jan;27(1):58-67. doi: 10.1002/jbmr.535.
PMID 21976359
 
Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.
Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, Kakehi Y.
Endocrinology. 2004 Jun;145(6):2929-40. Epub 2004 Feb 26.
PMID 14988385
 
Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney.
Sawai K, Mukoyama M, Mori K, Kasahara M, Koshikawa M, Yokoi H, Yoshioka T, Ogawa Y, Sugawara A, Nishiyama H, Yamada S, Kuwahara T, Saleem MA, Shiota K, Ogawa O, Miyazato M, Kangawa K, Nakao K.
Am J Physiol Renal Physiol. 2007 Oct;293(4):F1363-72. Epub 2007 Aug 15.
PMID 17699553
 
Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions.
Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP, Ye RD, Lau LF, Lam SC.
Blood. 2002 Jun 15;99(12):4457-65.
PMID 12036876
 
Identification of a complex congenital heart defect susceptibility locus by using DNA pooling and shared segment analysis.
Sheffield VC, Pierpont ME, Nishimura D, Beck JS, Burns TL, Berg MA, Stone EM, Patil SR, Lauer RM.
Hum Mol Genet. 1997 Jan;6(1):117-21.
PMID 9002679
 
Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice.
Su AI, Guidotti LG, Pezacki JP, Chisari FV, Schultz PG.
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11181-6. Epub 2002 Aug 12.
PMID 12177410
 
Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer.
Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C, Koeffler HP.
J Biol Chem. 2001 Dec 14;276(50):47709-14. Epub 2001 Oct 11.
PMID 11598125
 
Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R.
Oncogene. 2002 Nov 21;21(53):8178-85.
PMID 12444554
 
Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
Watari H, Xiong Y, Hassan MK, Sakuragi N.
Gynecol Oncol. 2009 Jan;112(1):229-34. doi: 10.1016/j.ygyno.2008.09.039. Epub 2008 Nov 12.
PMID 19007976
 
Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.
Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP.
Cancer Res. 2001 Dec 15;61(24):8917-23
PMID 11751417
 
Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas.
Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP.
Clin Cancer Res. 2004b Mar 15;10(6):2072-81.
PMID 15041728
 
Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface.
Yang GP, Lau LF.
Cell Growth Differ. 1991 Jul;2(7):351-7.
PMID 1782153
 
Elevation of angiogenic factor Cysteine-rich 61 levels in vitreous of patients with proliferative diabetic retinopathy.
You JJ, Yang CM, Chen MS, Yang CH.
Retina. 2012 Jan;32(1):103-11. doi: 10.1097/IAE.0b013e318219e4ad.
PMID 21822163
 
A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.
Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, Ouyang G, Lin J, Shen B, Shi Y, Zhang Y, Li D, Li N.
Arthritis Rheum. 2009 Dec;60(12):3602-12. doi: 10.1002/art.24999.
PMID 19950293
 
Cysteine-rich 61 (CYR61) is up-regulated in proliferative diabetic retinopathy.
Zhang X, Yu W, Dong F.
Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):661-8. doi: 10.1007/s00417-011-1882-7. Epub 2011 Dec 13.
PMID 22160564
 
MicroRNA-155 contributes to preeclampsia by down-regulating CYR61.
Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, Hu Y.
Am J Obstet Gynecol. 2010 May;202(5):466.e1-7. doi: 10.1016/j.ajog.2010.01.057.
PMID 20452491
 

Citation

This paper should be referenced as such :
Chen, CC ; Lau, LF
CYR61 (cysteine-rich, angiogenic inducer, 61)
Atlas Genet Cytogenet Oncol Haematol. 2013;17(7):445-452.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/CYR61ID40256ch1p22.html


External links

Nomenclature
HGNC (Hugo)CYR61   2654
Cards
AtlasCYR61ID40256ch1p22
Entrez_Gene (NCBI)CYR61  3491  cysteine rich angiogenic inducer 61
AliasesCCN1; GIG1; IGFBP10
GeneCards (Weizmann)CYR61
Ensembl hg19 (Hinxton)ENSG00000142871 [Gene_View]  chr1:86046444-86049648 [Contig_View]  CYR61 [Vega]
Ensembl hg38 (Hinxton)ENSG00000142871 [Gene_View]  chr1:86046444-86049648 [Contig_View]  CYR61 [Vega]
ICGC DataPortalENSG00000142871
TCGA cBioPortalCYR61
AceView (NCBI)CYR61
Genatlas (Paris)CYR61
WikiGenes3491
SOURCE (Princeton)CYR61
Genetics Home Reference (NIH)CYR61
Genomic and cartography
GoldenPath hg19 (UCSC)CYR61  -     chr1:86046444-86049648 +  1p22.3   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)CYR61  -     1p22.3   [Description]    (hg38-Dec_2013)
EnsemblCYR61 - 1p22.3 [CytoView hg19]  CYR61 - 1p22.3 [CytoView hg38]
Mapping of homologs : NCBICYR61 [Mapview hg19]  CYR61 [Mapview hg38]
OMIM602369   
Gene and transcription
Genbank (Entrez)AF003114 AF003594 AF031385 AK096420 AK223385
RefSeq transcript (Entrez)NM_001554
RefSeq genomic (Entrez)NC_000001 NC_018912 NT_032977 NW_004929290
Consensus coding sequences : CCDS (NCBI)CYR61
Cluster EST : UnigeneHs.8867 [ NCBI ]
CGAP (NCI)Hs.8867
Alternative Splicing GalleryENSG00000142871
Gene ExpressionCYR61 [ NCBI-GEO ]   CYR61 [ EBI - ARRAY_EXPRESS ]   CYR61 [ SEEK ]   CYR61 [ MEM ]
Gene Expression Viewer (FireBrowse)CYR61 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)3491
GTEX Portal (Tissue expression)CYR61
Protein : pattern, domain, 3D structure
UniProt/SwissProtO00622   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO00622  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO00622
Splice isoforms : SwissVarO00622
PhosPhoSitePlusO00622
Domaine pattern : Prosite (Expaxy)CTCK_1 (PS01185)    CTCK_2 (PS01225)    IGFBP_N_1 (PS00222)    IGFBP_N_2 (PS51323)    TSP1 (PS50092)    VWFC_1 (PS01208)    VWFC_2 (PS50184)   
Domains : Interpro (EBI)Cys_knot_C    Glyco_hormone_CN    Growth_fac_rcpt_    IGFBP-like    IGFBP_CNN    Insulin_GF-bd_Cys-rich_CS    TSP1_rpt    VWF_dom   
Domain families : Pfam (Sanger)Cys_knot (PF00007)    IGFBP (PF00219)    VWC (PF00093)   
Domain families : Pfam (NCBI)pfam00007    pfam00219    pfam00093   
Domain families : Smart (EMBL)CT (SM00041)  IB (SM00121)  TSP1 (SM00209)  VWC (SM00214)  
Conserved Domain (NCBI)CYR61
DMDM Disease mutations3491
Blocks (Seattle)CYR61
PDB (SRS)4D0Z    4D11   
PDB (PDBSum)4D0Z    4D11   
PDB (IMB)4D0Z    4D11   
PDB (RSDB)4D0Z    4D11   
Structural Biology KnowledgeBase4D0Z    4D11   
SCOP (Structural Classification of Proteins)4D0Z    4D11   
CATH (Classification of proteins structures)4D0Z    4D11   
SuperfamilyO00622
Human Protein AtlasENSG00000142871
Peptide AtlasO00622
HPRD09089
IPIIPI00299219   IPI00909871   IPI01011485   IPI00004792   IPI00006273   
Protein Interaction databases
DIP (DOE-UCLA)O00622
IntAct (EBI)O00622
FunCoupENSG00000142871
BioGRIDCYR61
STRING (EMBL)CYR61
ZODIACCYR61
Ontologies - Pathways
QuickGOO00622
Ontology : AmiGOregulation of cell growth  osteoblast differentiation  positive regulation of protein phosphorylation  intussusceptive angiogenesis  atrioventricular valve morphogenesis  apoptotic process involved in heart morphogenesis  ventricular septum development  integrin binding  insulin-like growth factor binding  proteinaceous extracellular matrix  chemotaxis  cell adhesion  cell-cell signaling  heparin binding  cell proliferation  anatomical structure morphogenesis  positive regulation of phospholipase activity  positive regulation of cell-substrate adhesion  extracellular matrix organization  positive regulation of cell migration  positive regulation of BMP signaling pathway  extracellular matrix  positive regulation of osteoblast proliferation  negative regulation of apoptotic process  positive regulation of cysteine-type endopeptidase activity involved in apoptotic process  wound healing, spreading of cells  positive regulation of osteoblast differentiation  positive regulation of protein kinase activity  positive regulation of transcription from RNA polymerase II promoter  extracellular matrix binding  atrial septum morphogenesis  negative regulation of cell death  chondroblast differentiation  chorio-allantoic fusion  labyrinthine layer blood vessel development  positive regulation of cartilage development  regulation of ERK1 and ERK2 cascade  reactive oxygen species metabolic process  positive regulation of ceramide biosynthetic process  
Ontology : EGO-EBIregulation of cell growth  osteoblast differentiation  positive regulation of protein phosphorylation  intussusceptive angiogenesis  atrioventricular valve morphogenesis  apoptotic process involved in heart morphogenesis  ventricular septum development  integrin binding  insulin-like growth factor binding  proteinaceous extracellular matrix  chemotaxis  cell adhesion  cell-cell signaling  heparin binding  cell proliferation  anatomical structure morphogenesis  positive regulation of phospholipase activity  positive regulation of cell-substrate adhesion  extracellular matrix organization  positive regulation of cell migration  positive regulation of BMP signaling pathway  extracellular matrix  positive regulation of osteoblast proliferation  negative regulation of apoptotic process  positive regulation of cysteine-type endopeptidase activity involved in apoptotic process  wound healing, spreading of cells  positive regulation of osteoblast differentiation  positive regulation of protein kinase activity  positive regulation of transcription from RNA polymerase II promoter  extracellular matrix binding  atrial septum morphogenesis  negative regulation of cell death  chondroblast differentiation  chorio-allantoic fusion  labyrinthine layer blood vessel development  positive regulation of cartilage development  regulation of ERK1 and ERK2 cascade  reactive oxygen species metabolic process  positive regulation of ceramide biosynthetic process  
NDEx NetworkCYR61
Atlas of Cancer Signalling NetworkCYR61
Wikipedia pathwaysCYR61
Orthology - Evolution
OrthoDB3491
GeneTree (enSembl)ENSG00000142871
Phylogenetic Trees/Animal Genes : TreeFamCYR61
HOVERGENO00622
HOGENOMO00622
Homologs : HomoloGeneCYR61
Homology/Alignments : Family Browser (UCSC)CYR61
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerCYR61 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)CYR61
dbVarCYR61
ClinVarCYR61
1000_GenomesCYR61 
Exome Variant ServerCYR61
ExAC (Exome Aggregation Consortium)CYR61 (select the gene name)
Genetic variants : HAPMAP3491
Genomic Variants (DGV)CYR61 [DGVbeta]
DECIPHER (Syndromes)1:86046444-86049648  ENSG00000142871
CONAN: Copy Number AnalysisCYR61 
Mutations
ICGC Data PortalCYR61 
TCGA Data PortalCYR61 
Broad Tumor PortalCYR61
OASIS PortalCYR61 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICCYR61  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDCYR61
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch CYR61
DgiDB (Drug Gene Interaction Database)CYR61
DoCM (Curated mutations)CYR61 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)CYR61 (select a term)
intoGenCYR61
NCG5 (London)CYR61
Cancer3DCYR61(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM602369   
Orphanet
MedgenCYR61
Genetic Testing Registry CYR61
NextProtO00622 [Medical]
TSGene3491
GENETestsCYR61
Huge Navigator CYR61 [HugePedia]
snp3D : Map Gene to Disease3491
BioCentury BCIQCYR61
ClinGenCYR61
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD3491
Chemical/Pharm GKB GenePA27126
Clinical trialCYR61
Miscellaneous
canSAR (ICR)CYR61 (select the gene name)
Probes
Litterature
PubMed187 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineCYR61
EVEXCYR61
GoPubMedCYR61
iHOPCYR61
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:39:02 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.